R&D Harnessing the velocity of biopharmaceutical advances Today’s pharmaphorum podcast addresses the subject of speed – the velocity at which biopharma is bringing new therapies and medicines to market faster.
News Zymeworks cuts deal to buy Theravance for $929m in cash Zymeworks has reached a deal to buy Theravance, claiming rights to COPD therapy Yupelri, sold by Viatris, which made $267m last year.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.